Edgewise Therapeutics, Inc.
EWTXNasdaq
$39.76
↑ +4.1%Jul 17 close · end-of-day
Price
1Y↑ +191.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$4.3B
Enterprise Value
$4.2B
P/E
—
P/S
—
P/B
8.6
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$8.4M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-1.7%
ROIC
-34.3%
Debt / Equity
—
Net Cash
$33.2M
Return 1Y
+189.6%
Company profile
Edgewise Therapeutics, Inc. develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy.
- CEO
- Kevin Koch
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 60
- Headquarters
- Colorado
- Website
- edgewisetx.com
Management & directors
- Russell Alan JChief Scientific Officer
- Donovan Joanne M.CMO
- Carruthers R MichaelChief Financial Officer
- Derakhshan BehradChief Business Officer
- Koch KevinPresident and CEO
- Moore John RGeneral Counsel
Roles derived from SEC Form 4 filings.
Earnings
EWTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.46↑ +7.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$17.2M | -$43.2M | -$71.7M | -$114.4M | -$158.8M | -$191.4M |
| Net income | -$17.1M | -$42.8M | -$67.6M | -$100,163.00 | -$133,813.00 | -$167,795.00 |
| Diluted EPS | -$23.17 | -$1.14 | -$1.26 | -$1.57 | -$1.45 | -$1.63 |
| Operating cash flow | -$14.6M | -$33.5M | -$52.6M | -$91.9M | -$109.0M | -$143.8M |
| Free cash flow | -$14.8M | -$34.2M | -$58.2M | -$97.7M | -$110.3M | -$144.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$38.1M | -$40.4M | -$45.5M | -$46.0M | -$42.6M | -$46.9M | -$56.0M | -$54.1M |
| Net income | -$31.5M | -$34.1M | $94.0M | -$40.8M | -$36.1M | -$40.7M | $117.4M | -$49.0M |
| Diluted EPS | -$0.34 | -$0.36 | -$0.42 | -$0.43 | -$0.34 | -$0.39 | -$0.47 | -$0.46 |
| Operating cash flow | -$26.1M | -$27.4M | -$27.0M | -$37.9M | -$32.6M | -$34.8M | -$38.6M | -$42.5M |
| Free cash flow | -$26.3M | -$27.9M | -$27.2M | -$37.9M | — | — | — | -$42.8M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 17, 2026
Jul 13, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Russell Alan J· Chief Scientific Officer | Sale | 130,352 | $39.41 | $5.1M | filing |
| 2026-07-01 | Russell Alan J· Chief Scientific Officer | Sale | 69,648 | $39.41 | $2.7M | filing |
| 2026-07-01 | Russell Alan J· Chief Scientific Officer | Option exercise | 130,352 | $0.45 | $58,658.40 | filing |
| 2026-07-01 | Russell Alan J· Chief Scientific Officer | Option exercise | 69,648 | $0.18 | $12,536.64 | filing |
| 2026-07-01 | Fox Jonathan C | Award | 319 | $0.00 | $0.00 | filing |
| 2026-05-05 | Donovan Joanne M.· CMO | Sale | 50,000 | $38.57 | $1.9M | filing |
| 2026-05-05 | Donovan Joanne M.· CMO | Option exercise | 50,000 | $7.08 | $354,000.00 | filing |
| 2026-05-04 | Donovan Joanne M.· CMO | Sale | 5,230 | $31.29 | $163,662.91 | filing |
| 2026-04-01 | Donovan Joanne M.· CMO | Sale | 28,662 | $32.31 | $926,095.02 | filing |
| 2026-04-01 | Donovan Joanne M.· CMO | Option exercise | 28,662 | $7.08 | $202,926.96 | filing |
| 2026-04-01 | Fox Jonathan C | Award | 339 | $0.00 | $0.00 | filing |
| 2026-03-31 | Donovan Joanne M.· CMO | Sale | 21,338 | $32.12 | $685,308.28 | filing |
| 2026-03-31 | Donovan Joanne M.· CMO | Option exercise | 21,338 | $7.08 | $151,073.04 | filing |
| 2026-03-27 | Donovan Joanne M.· CMO | Sale | 9,623 | $30.98 | $298,099.37 | filing |
| 2026-03-27 | Donovan Joanne M.· CMO | Sale | 6,735 | $30.98 | $208,635.48 | filing |
| 2026-01-21 | Edris Badreddin | Sale | 66,477 | $29.44 | $2.0M | filing |
| 2026-01-21 | Edris Badreddin | Sale | 17,236 | $29.44 | $507,427.84 | filing |
| 2026-01-21 | Edris Badreddin | Sale | 13,690 | $29.44 | $403,033.60 | filing |
| 2026-01-21 | Edris Badreddin | Sale | 10,463 | $29.44 | $308,030.72 | filing |
| 2026-01-21 | Edris Badreddin | Sale | 7,605 | $29.44 | $223,891.20 | filing |
| 2026-01-21 | Edris Badreddin | Option exercise | 66,477 | $1.93 | $128,300.61 | filing |
| 2026-01-21 | Edris Badreddin | Option exercise | 10,463 | $1.93 | $20,193.59 | filing |
| 2026-01-21 | Edris Badreddin | Option exercise | 17,236 | $0.64 | $11,031.04 | filing |
| 2026-01-21 | Edris Badreddin | Option exercise | 7,605 | $0.71 | $5,399.55 | filing |
| 2026-01-21 | Edris Badreddin | Option exercise | 13,690 | $0.39 | $5,339.10 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.